About: NanOlogy
Profile:
Posts by NanOlogy:
- NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer (May 3, 2022 - Home Page, NanOlogy Press Release)
- Breast Cancer Research & Treatment: Phase 1/2 Study of Topical Submicron Particle Paclitaxel for Cutaneous Metastases of Breast Cancer (April 26, 2022 - Publications)
- Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care (November 9, 2021 - Home Page, NanOlogy Press Release)
- ACG 2021 Presentation: Improved Resection Rates in Locally Advanced Pancreatic Cancer (LAPC) Following EUS-FNI of Large Surface Area Microparticle Paclitaxel (LSAM Pac) (November 3, 2021 - Presentations)
- OncLive: LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach (September 16, 2021 - NanOlogy in the News)
- Target Oncology: Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC (September 16, 2021 - NanOlogy in the News)
- Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions (August 24, 2021 - Home Page, Publications)
- Additional Data Presented at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas (June 9, 2021 - Home Page, NanOlogy Press Release)
- DDW 2021 Poster: Tandem EUS-Guided Fine Needle Injection of Intracystic Submicron Particle Paclitaxel (Nanopac®) as a Treatment for Branch-Duct IPMN: Safety, Pharmacokinetic, and Preliminary Efficiency (June 2, 2021 - Presentations)
- NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical Trial (April 26, 2021 - Home Page, NanOlogy Press Release)
- JACS: Surgery is a viable treatment for pancreatic cancer patients especially after chemotherapy (March 26, 2021 - NanOlogy in the News, Uncategorized)
- NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial (March 9, 2021 - Home Page, NanOlogy Press Release)
- NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical Trial in the Treatment of Cutaneous Metastases at 2020 SABCS® (December 29, 2020 - NanOlogy Press Release)
- SABCS 2020 Poster: Phase 1/2 Clinical Trial of A Topical Submicron Particle Paclitaxel (SOR007) for the Treatment of Cutaneous Metastases (December 17, 2020 - Presentations)
- Drug Delivery and Translational Research: Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies (November 10, 2020 - Home Page, Publications)
- NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer (November 4, 2020 - Home Page, NanOlogy Press Release)
- Gynecologic Oncology Reports: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery (September 17, 2020 - Home Page, Publications)
- ASCO 2020 Abstract: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer undergoing cytoreductive surgery (July 2, 2020 - Presentations)
